[{"address1": "2450 Holcombe Boulevard", "address2": "Suite X", "city": "Houston", "state": "TX", "zip": "77021", "country": "United States", "phone": "832 834 9144", "website": "https://www.salariuspharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.", "fullTimeEmployees": 2, "maxAge": 86400, "priceHint": 4, "previousClose": 2.81, "open": 2.7311, "dayLow": 2.505, "dayHigh": 2.7414, "regularMarketPreviousClose": 2.81, "regularMarketOpen": 2.7311, "regularMarketDayLow": 2.505, "regularMarketDayHigh": 2.7414, "beta": 0.971, "forwardPE": -0.013404255, "volume": 23171, "regularMarketVolume": 23171, "averageVolume": 18958, "averageVolume10days": 46205, "averageDailyVolume10Day": 46205, "bid": 2.43, "ask": 2.78, "bidSize": 100, "askSize": 100, "marketCap": 1504576, "fiftyTwoWeekLow": 2.505, "fiftyTwoWeekHigh": 12.48, "fiftyDayAverage": 3.76676, "twoHundredDayAverage": 4.86177, "currency": "USD", "enterpriseValue": -2751774, "floatShares": 559726, "sharesOutstanding": 597054, "sharesShort": 4185, "sharesShortPriorMonth": 14451, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0069999998, "heldPercentInsiders": 0.060760003, "heldPercentInstitutions": 0.04033, "shortRatio": 1.19, "shortPercentOfFloat": 0.0070999996, "impliedSharesOutstanding": 597054, "bookValue": 6.767, "priceToBook": 0.37239543, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8917210, "trailingEps": -16.16, "forwardEps": -188.0, "lastSplitFactor": "1:8", "lastSplitDate": 1718582400, "enterpriseToEbitda": 0.298, "52WeekChange": -0.775, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLRX", "underlyingSymbol": "SLRX", "shortName": "Salarius Pharmaceuticals, Inc.", "longName": "Salarius Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1422541800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f7c5d494-3e4a-33bc-9704-e2b0ec3dd19f", "messageBoardId": "finmb_330031056", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.52, "targetHighPrice": 26.0, "targetLowPrice": 26.0, "targetMeanPrice": 26.0, "targetMedianPrice": 26.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 4373205, "totalCashPerShare": 7.325, "ebitda": -9236407, "totalDebt": 116855, "quickRatio": 3.544, "currentRatio": 3.914, "debtToEquity": 3.202, "returnOnAssets": -0.77365, "returnOnEquity": -1.93676, "freeCashflow": -8539666, "operatingCashflow": -11030657, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]